AIDSVAX results: an important open question.
Research and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis.
Veljkovic
Veljko
V
Center for Multidisciplinary Research, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, Yugoslavia. veljko01@hotmail.com
Müller
Sybille
S
Köhler
Heinz
H
D016915:AIDS Vaccines; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006801:Humans
D016915:AIDS Vaccines